Log in
NYSE:TAK

Takeda Pharmaceutical Stock Forecast, Price & News

$18.53
0.00 (0.00 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$18.32
Now: $18.53
$18.55
50-Day Range
$17.97
MA: $18.52
$19.19
52-Week Range
$12.43
Now: $18.53
$20.92
Volume968,017 shs
Average Volume1.30 million shs
Market Capitalization$58.42 billion
P/E Ratio41.18
Dividend Yield3.29%
Beta0.99
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. to evaluate the investigational biologic TAK-079 as a potential new therapy for Lupus in a Phase 1 trial. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone813-3278-2111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.20 billion
Cash Flow$3.49 per share
Book Value$13.80 per share

Profitability

Net Income$407.02 million

Miscellaneous

Employees47,495
Outstanding Shares3,152,748,000
Market Cap$58.42 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$18.53
0.00 (0.00 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

How has Takeda Pharmaceutical's stock price been impacted by COVID-19?

Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TAK shares have increased by 8.0% and is now trading at $18.53.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Takeda Pharmaceutical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Takeda Pharmaceutical
.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Takeda Pharmaceutical
.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Co Ltd (NYSE:TAK) released its quarterly earnings data on Friday, July, 31st. The company reported $0.57 earnings per share (EPS) for the quarter. The business had revenue of $7.46 billion for the quarter. Takeda Pharmaceutical had a net margin of 4.57% and a return on equity of 13.89%.
View Takeda Pharmaceutical's earnings history
.

What price target have analysts set for TAK?

2 brokers have issued 1 year price targets for Takeda Pharmaceutical's shares. Their forecasts range from $19.50 to $30.00. On average, they anticipate Takeda Pharmaceutical's stock price to reach $24.75 in the next year. This suggests a possible upside of 33.6% from the stock's current price.
View analysts' price targets for Takeda Pharmaceutical
.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 2,280,000 shares, a decline of 18.0% from the August 31st total of 2,780,000 shares. Based on an average daily trading volume, of 1,000,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 0.1% of the company's shares are short sold.
View Takeda Pharmaceutical's Short Interest
.

Who are some of Takeda Pharmaceutical's key competitors?

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), Gilead Sciences (GILD), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:
  • Mr. Christophe Weber, Pres, CEO & Representative Director (Age 53)
  • Dr. Andrew S. Plump, Chief Medical & Scientific Officer and Director (Age 54)
  • Dr. Seigo Izumo M.D., Chair of Management Board
  • Mr. Costa Saroukos, Chief Financial Officer (Age 48)
  • Mr. Haruhiko Hirate, Member of Management Board & Corp. Communications and Public Affairs Officer (Age 62)

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Paulson & CO. Inc. (0.36%), Adelphi Capital LLP (0.29%), Vanguard Group Inc. (0.14%), Macquarie Group Ltd. (0.13%), Bank of America Corp DE (0.10%) and Mondrian Investment Partners LTD (0.10%).

Which major investors are selling Takeda Pharmaceutical stock?

TAK stock was sold by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Vanguard Group Inc., Macquarie Group Ltd., Mondrian Investment Partners LTD, Brandes Investment Partners LP, Adelphi Capital LLP, CIBC Asset Management Inc, and PNC Financial Services Group Inc..

Which major investors are buying Takeda Pharmaceutical stock?

TAK stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Teacher Retirement System of Texas, Goldman Sachs Group Inc., Canada Pension Plan Investment Board, Schonfeld Strategic Advisors LLC, Aigen Investment Management LP, Marshall Wace LLP, and FMR LLC.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $18.53.

How big of a company is Takeda Pharmaceutical?

Takeda Pharmaceutical has a market capitalization of $58.42 billion and generates $30.20 billion in revenue each year. The company earns $407.02 million in net income (profit) each year or $1.78 on an earnings per share basis. Takeda Pharmaceutical employs 47,495 workers across the globe.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takeda.com.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company can be reached via phone at 813-3278-2111.

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.